Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents.
Repligen's Q4 Slightly Tops Expectations
Repligen (RGEN 7.92%), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimate of $0.41, but fell year over year.
Repligen (RGEN) Beats Q4 Earnings Estimates
Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago.
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Repligen price target lowered to $180 from $240 at H.C. Wainwright
H.C. Wainwright lowered the firm's price target on Repligen to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in the coming year. It lowered the price target saying Repligen's "explosive growth" of the COVID-19 years is no longer evident, but notes that the company's risk profile and overall positioning remain attractive.
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Evan Stock - Wells Fargo Matthew Hewitt - Craig-Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Matt Stanton - Jefferies LLC Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Third Quarter of 2024 Earnings Conference Call.
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago.
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty.
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
